parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	compounds already reach it: neihulizumab	0.81
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 94	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 8425

SELPLG in dopamine neurons, braak-0.46 (p 0.212) → -0.17 (p 0.655)receipt 8434
SELPLG in microglia, braak-0.82 (p 0.007) → +0.26 (p 0.507)receipt 8433

receipt 8434: SELPLG in dopamine neurons, braak

power: full sample -0.35 (p 0.153, n 18), 95% CI -0.70 to +0.14. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.232, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.176, n 18). could be the mix.
skeptic: leave-one-out range -0.44 to -0.26, sign flips 0; without severely affected donors -0.35 (p 0.153, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SELPLG in dopamine neurons.

case closed: nothing better to follow up.

receipt 8433: SELPLG in microglia, braak

power: full sample -0.34 (p 0.164, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.16 (p 0.532, n 18). could be the mix.
skeptic: leave-one-out range -0.51 to -0.26, sign flips 0; without severely affected donors -0.34 (p 0.164, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SELPLG in microglia.

case closed: nothing better to follow up.

loading the receipts